RecruitingPhase 1Phase 2NCT05092451

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Sponsor

M.D. Anderson Cancer Center

Enrollment

80 participants

Start Date

Nov 1, 2022

Study Type

INTERVENTIONAL

Conditions

Hodgkin Lymphoma Multiple Myeloma Acute Myeloid Leukemia (AML)B-cell Lymphoma Myelodysplastic Syndromes (MDS)Plasma Cell Leukemia T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia Blastic Transformation of Chronic Myeloid Leukemia Germ Cell Tumors

Summary

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

Eligibility

Min Age: 12 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of cell therapy for blood cancers that have not responded to standard treatment. It uses specially engineered natural killer (NK) cells from umbilical cord blood — a type of immune cell — that are designed to find and destroy cancer cells. **You may be eligible if...** - You have a blood cancer (such as leukemia, lymphoma, or myeloma) that has come back or is not responding to treatment - Your tumor cells express a marker called CD70 (confirmed by testing) - You are in reasonable overall health (Karnofsky or Lansky score ≥ 50) - Your organ function (kidneys, liver, heart) meets minimum requirements - You are at least 1 week out from your last chemotherapy **You may NOT be eligible if...** - Your CD70 marker is low or absent on tumor cells - You have severe organ dysfunction - You have active uncontrolled infection - You are pregnant or breastfeeding - You are unable or unwilling to comply with study requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.